ImmunoCellular Therapeutics ($IMUC) announced suspending patient randomization for its Phase 3 clinical trial assessing lead product candidate ICT-107 for the treatment of newly diagnosed glioblastoma. The company reported the paucity of financial resources as the reason behind the decision. The company also said that it will continue explore strategic alternatives including a merger, reorganization or other business combination.
Cara Therapeutics ($CARA) reported disappointing results from an interim analysis of a Phase 3 clinical trial assessing IV CR845 for the treatment of post-operative pain in patients undergoing abdominal surgery. The Independent Data Monitoring Committee recommended that the study continue to test both doses of CR845, which implies that the study has not met its primary endpoint.